Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 7/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.56 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 5/20 | 0.52 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10960299 | 0.83 | TOP2A (0.50) | EGFRTP53SMN1; SMN2GAARAB9A | |
| SCHEMBL10339770 | 0.83 | POLB (0.56) | AURKBEGFRPDE4B | |
| Hydrochloric Acid SCHEMBL10958209 | 0.81 | MAPK1 (0.55) | AURKBEGFRGAAHTTPDE4B | |
| SCHEMBL15101055 | 0.80 | KMT2A (0.49) | EGFRTP53SMN1; SMN2GAARAB9A | |
| SCHEMBL4908957 | 0.78 | PDE4B (0.50) | AURKATP53SMN1; SMN2NPC1GAA | |
| SCHEMBL11012199 | 0.78 | RAB9A (0.53) | TP53SMN1; SMN2NPC1RAB9APDE4B | |
| SCHEMBL15101054 | 0.76 | MKNK1 (0.50) | AURKBEGFRAURKAPDE4BIRAK4 | |
| SCHEMBL10956616 | 0.74 | EGFR (0.56) | EGFRSMN1; SMN2NPC1GAAHTT | |
| SCHEMBL10955880 | 0.74 | MKNK1 (0.54) | EGFRSMN1; SMN2GAAHTTKDR | |
| SCHEMBL10960189 | 0.74 | MKNK1 (0.54) | GAAHTTKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYNTOVIA, INC. (US) | 2008-05-15 | — | — | US | claimed |
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYNTOVIA, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYNTOVIA, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYNTOVIA, INC. (US) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP7, API5, CASP5 | AURKB 267/4885EGFR 2294/4885INCENP 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.